Validation of a Novel Smartphone-based Method for Heart Rhythm Monitoring in the Home Environment

NCT ID: NCT04300270

Last Updated: 2025-03-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

480 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-11-27

Study Completion Date

2025-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Atrial fibrillation is a heart rhythm disorder with increased risk of stroke, heart failure, dementia and death. The severity of symptoms in atrial fibrillation varies markedly, ranging from no symptoms to those with disabling symptoms. An ECG recording is currently mandatory for diagnosing atrial fibrillation. A portable method for heart rhythm diagnostics that is readily available is currently missing in clinical practice. If a standard smartphone could be used for heart rhythm diagnostics, the availability could improve greatly.

Treatment with direct current cardioversion is a procedure in which the heart rhythm is normalized by an electrical shock through the chest. Patients with atrial fibrillation are in some cases recommended treatment with direct current cardioversion but the procedure is costly, has a high recurrence rate and includes an increased risk for stroke. In this study we will validate the use of a novel smartphone-based method for heart rhythm diagnostics when used by patients in their home environment. The novel method is using the smartphone camera as a sensor. Patients will be doing heart rhythm measurements with the novel smartphone-based method in their home environment for 30 days after successfully receiving treatment of atrial fibrillation with direct current cardioversion. The novel smartphone-based method will be validated against simultaneous recordings with mobile ECG.

We will also study the feasibility in using smartphone recordings and mobile ECG in the home environment the weeks before receiving treatment with direct current cardioversion, to study the possible benefit of detecting spontaneous conversions to normal heart rhythm and missed doses of treatment with blood thinning medication, both of which will lead to cancellation or detention of the cardioversion procedure.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Atrial fibrillation is a heart rhythm disorder with increased risk of stroke, heart failure, dementia and death. The severity of symptoms in atrial fibrillation varies markedly, ranging from no symptoms to those with disabling symptoms. An ECG recording is currently mandatory for diagnosing atrial fibrillation.

The availability of long-term ECG and portable ECG registration for heart rhythm diagnostics within the healthcare sector is severely limited by waiting time both for ECG recording and for analysis and reporting. A method for heart rhythm diagnostics that is readily available is currently lacking in clinical practice, except for hospitalization, which is very costly and has low availability.

The lack of a method for diagnosis of heart rhythm disorders and atrial fibrillation that is readily available, cost-effective and simple to use is a problem for both the patients and for the healthcare system as a whole. The limited availability of patient-related diagnostics thus means that many patients, even those with symptoms, remain undiagnosed and thus untreated, which in turn means that the missing diagnosis gives an increased risk of stroke. If a standard smartphone could be used for reliable heart rhythm diagnostics, the availability could improve greatly.

Treatment with direct current cardioversion is a procedure in which the heart rhythm is normalized by an electrical shock through the chest. Patients with atrial fibrillation could in some cases be treated with cardioversion but the procedure is costly, has a high recurrence rate and includes an increased risk for thromboembolism and stroke. The benefit of the treatment is mainly symptomatic, with no proven long-term effects of mortality or morbidity.

In this study we will validate the use of a novel smartphone-based method for heart rhythm diagnostics when used by patients in their home environment after receiving treatment with direct current cardioversion. The novel method is using the smartphone camera as a sensor and records photoplethysmographic (PPG) measurements. We will also study the feasibility in using smartphone and mobile ECG recordings peri-cardioversion, to study the possible benefit of detecting pre-cardioversion spontaneous conversions to sinus rhythm and non-adherence to treatment with oral anticoagulants, both of which will lead to cancellation or detention of the cardioversion procedure. We will also detect the timing of post-cardioversion early recurrences into atrial fibrillation, as well as the heart rate and symptoms associated to recurrence, if any.

The objective of this study is to:

1. Validate heart rhythm measurements registered with a novel smartphone-based method using PPG-measurement technology compared to mobile ECG technology in patients with atrial fibrillation. The validation involves evaluating whether PPG-measurement technology using a novel smartphone-based method provides sufficient diagnostic performance in the home environment / outpatient environment compared to outpatient mobile ECG measurements.
2. Study if pre-cardioversion heart rhythm recordings will reduce the number of same day cancellations of treatment of atrial fibrillation with planned direct current cardioversion.

For the validation part, patients who visit the cardiac day care department at the department of Cardiology, Danderyd University Hospital, for treatment with outpatient direct current cardioversion of atrial fibrillation or atrial flutter are asked about participating by physicians or research nurses. Each patient will prior to inclusion in the study be given full and adequate verbal and written information regarding the objective and procedures of the study and possible risks involved. Written consent is obtained from the physician or research nurse.

A 60-second heart rhythm measurement using a smartphone is recorded before the patient receives treatment with direct current cardioversion. The smartphone used is the same device that the patient will be using in their home for 30 days after the treatment. The measurement includes PPG-measurement from the camera of the smartphone as well as a simultaneous one lead ECG-registration done with a small ECG-device attached to the back of the smartphone.

The patient is interviewed about their medical history and their current symptoms. If the treatment is successful and the patient's heart rhythm is converted back to normal sinus rhythm, the patient is included in the study. The patient's heart rhythm is verified with an ECG measurement recorded approximately one hour after the cardioversion treatment.

When the patients are discharged from the hospital they are given a smartphone that they will be recording simultaneous PPG- and ECG-recordings with, at least twice daily for a period of 30 days post-cardioversion in their home.

For the clinical implementation part, patients scheduled for direct current cardioversion at Danderyd University Hospital will be included at least 2 weeks prior to the scheduled treatment. Information regarding co-morbidities, echocardiographic parameters and current medication will be collected from interviews and medical records.

All individuals scheduled for direct current cardioversion will be invited to a screening visit and asked to sign a written consent form. After consent, their heart rhythm will be recorded and those with sinus rhythm will be excluded. Participants with atrial fibrillation or atrial flutter will be randomized 1:1 to pre-cardioversion heart rhythm monitoring, or no monitoring pre-cardioversion.

Participants randomized to active pre-cardioversion rhythm monitoring (intervention group) will be instructed in the use of smartphone rhythm recordings (using simultaneous PPG and mobile ECG). They will be recording both their heart rhythm and oral anticoagulant treatment adherence with the same smartphone application. This information will give the investigators the possibility to cancel or postpone the scheduled cardioversion visit in advance for those with spontaneous rhythm conversion to sinus rhythm and for those with non-adherence to oral anticoagulant treatment.

Participants randomized to passive pre-cardioversion rhythm monitoring (control group) will be instructed in the use of smartphone rhythm recordings (using simultaneous PPG and mobile ECG). The control group will be recording only heart rhythm and not treatment adherence. The heart rhythm recordings made in the control group will be reviewed after the participants treatment with direct current cardioversion.

After the treatment with direct current cardioversion, all participants are followed up in one common cohort.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation Atrial Flutter Arrhythmia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Validation cohort

Participants in validation of the novel smartphone-based photoplethysmographic method for ambulatory heart rhythm diagnostics.

Smartphone PPG recordings

Intervention Type DEVICE

Smartphone camera PPG recordings using a novel software application.

Smartphone ECG

Intervention Type DEVICE

Smartphone connected one-lead ECG recordings.

Clinical implementation cohort

Participants in a clinical implementation of the novel smartphone-based photoplethysmographic method for ambulatory heart rhythm diagnostics.

Smartphone PPG recordings

Intervention Type DEVICE

Smartphone camera PPG recordings using a novel software application.

Smartphone ECG

Intervention Type DEVICE

Smartphone connected one-lead ECG recordings.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Smartphone PPG recordings

Smartphone camera PPG recordings using a novel software application.

Intervention Type DEVICE

Smartphone ECG

Smartphone connected one-lead ECG recordings.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Alivecor Kardia Mobile ECG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients undergoing direct current cardioversion successfully for treatment of atrial fibrillation or atrial flutter and have a normal heart rhythm after the treatment.


* Patients planned for direct current cardioversion for treatment of atrial fibrillation or atrial flutter.

Exclusion Criteria

* Patients with implantable cardiac devices.

Clinical implementation cohort:


* Patients with implantable cardiac devices.
* Patients with a spontaneous return to sinus rhythm diagnosed at a screening visit 2 to 4 weeks prior to the scheduled treatment with direct current cardioversion.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Danderyd Hospital

OTHER

Sponsor Role collaborator

Karolinska Institutet

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Johan Engdahl

Associate Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Johan Engdahl

Role: PRINCIPAL_INVESTIGATOR

Karolinska Institutet

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Danderyd University Hospital

Stockholm, , Sweden

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Sweden

References

Explore related publications, articles, or registry entries linked to this study.

Fernstad J, Svennberg E, Aberg P, Kemp Gudmundsdottir K, Jansson A, Engdahl J. External validation of a machine learning-based classification algorithm for ambulatory heart rhythm diagnostics in pericardioversion atrial fibrillation patients using smartphone photoplethysmography: the SMARTBEATS-ALGO study. Europace. 2025 Mar 28;27(4):euaf031. doi: 10.1093/europace/euaf031.

Reference Type DERIVED
PMID: 39960451 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SmartBeats

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.